2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
US10208024B2 · kind B2 · utility
27Cited by
20References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 24, 2016 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | Oct 24, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/574
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.